May 2026 in “Pharmaceuticals” Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
1 citations
,
September 2023 in “Rheumatology advances in practice” A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” Infliximab can trigger lupus-like symptoms in Crohn's disease patients.
January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
144 citations
,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
36 citations
,
December 2015 in “Drugs” New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
23 citations
,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
2 citations
,
March 2016 in “The Journal of Dermatology” The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
1 citations
,
September 2025 in “PLoS ONE” Certain drugs may cause vitiligo, so patients should be monitored.
1 citations
,
September 2023 in “Dermatology and therapy” More research is needed to find the best treatment for dissecting cellulitis of the scalp.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
June 2025 in “Saratov Medical Journal” Ongoing research and innovation are crucial for improving skin care and treatment.
May 2025 in “Galen Medical Journal” New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.
March 2023 in “Clinical, cosmetic and investigational dermatology” IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
July 2018 in “European Medical Journal” Fumaric acid esters, especially dimethylfumarate, improve psoriasis treatment.
Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.